Summary & Overview
CPT 87636: Multiplex Detection of COVID-19 and Influenza Viruses
CPT code 87636 represents a multiplex nucleic acid test for the detection of SARS‑CoV‑2 (COVID‑19) and influenza virus types A and B. This laboratory procedure is critical for identifying and differentiating respiratory infections, especially during periods of high viral activity. The code is widely used in hospital and independent laboratory settings, supporting timely diagnosis and management of patients with respiratory symptoms.
Major national payers, including Aetna, Blue Cross Blue Shield, Cigna Health, and UnitedHealthcare, provide coverage for this procedure, reflecting its importance in clinical practice and public health. Readers will gain insight into payer coverage, relevant clinical benchmarks, and policy updates related to laboratory testing for respiratory viruses. The publication also addresses associated clinical taxonomies, common billing modifiers, and ICD-10 diagnoses linked to this code, offering a comprehensive overview for stakeholders in laboratory medicine, billing, and healthcare policy.
This summary provides a national perspective on the utilization and reimbursement landscape for CPT code 87636, highlighting its role in the ongoing response to respiratory viral outbreaks and its integration into routine laboratory workflows.
CPT Code Overview
CPT code 87636 is used for the detection of infectious agents by nucleic acid (DNA or RNA), specifically targeting severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2), which causes Coronavirus disease (COVID‑19), as well as influenza virus types A and B. This procedure utilizes a multiplex amplified probe technique, allowing simultaneous testing for multiple respiratory pathogens. The service falls under Pathology and Laboratory Procedures – Microbiology and is typically performed in a laboratory setting, such as a hospital or independent laboratory. This code is essential for rapid and accurate diagnosis of respiratory infections, supporting clinical decision-making and public health efforts.
Clinical & Coding Specifications
Clinical Context
A patient presents to their healthcare provider with symptoms such as fever, cough, and sore throat during respiratory virus season. The provider orders a multiplex nucleic acid test to simultaneously detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza virus types A and B. The specimen is collected (typically a nasopharyngeal swab) and sent to a hospital or independent laboratory. The laboratory performs the test using an amplified probe technique, reporting results to the provider for clinical management. This workflow is common for patients with suspected COVID-19 or influenza, especially those with underlying immunodeficiency conditions.
Coding Specifications
- Modifier
QW: Indicates that the test is CLIA-waived and can be performed in laboratories with a CLIA Certificate of Waiver.
| Modifier Code | Description |
|---|---|
QW | CLIA-waived test |
- Provider Taxonomies: